Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2 Exit Filing)*
(Amendment No. 2 Exit Filing)*
BIOMX INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
(Title of Class of Securities)
09090D103
(CUSIP Number)
(CUSIP Number)
March 25, 2022
(Date of Event Which Requires Filing of this Statement)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 09090D103
| (1) | Names of reporting persons Takeda Pharmaceutical Company Limited | |||||||||||||||||||||||||||||||||||||
| (2) | Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐ | |||||||||||||||||||||||||||||||||||||
| (3) | SEC use only | |||||||||||||||||||||||||||||||||||||
| (4) | Citizenship or place of organization Japan | |||||||||||||||||||||||||||||||||||||
Number of shares beneficially owned by each reporting person with: | (5) | Sole voting power 0 | ||||||||||||||||||||||||||||||||||||
| (6) | Shared voting power 1,478,286 | |||||||||||||||||||||||||||||||||||||
| (7) | Sole dispositive power 0 | |||||||||||||||||||||||||||||||||||||
| (8) | Shared dispositive power 1,478,286 | |||||||||||||||||||||||||||||||||||||
| (9) | Aggregate amount beneficially owned by each reporting person 1,478,286 (1) | |||||||||||||||||||||||||||||||||||||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐ | |||||||||||||||||||||||||||||||||||||
| (11) | Percent of class represented by amount in Row (9) 4.96% (2) | |||||||||||||||||||||||||||||||||||||
| (12) | Type of reporting person (see instructions) CO | |||||||||||||||||||||||||||||||||||||
(1) Takeda Pharmaceutical Company Limited’s beneficial ownership of the issuer’s common stock (“Common Stock”) is comprised of 1,478,286 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (72.7%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.
(2) Based on 29,780,409 shares of Common Stock issued and outstanding as of May 5, 2022, as reported in the Issuer’s Form 10-Q, for the period ended March 31, 2022, filed with the Securities and Exchange Commission on May 11, 2022 (the “Form 10-Q”).
Page 2 of 7 pages
CUSIP No. 09090F103
| (1) | Names of reporting persons Takeda Ventures, Inc. | |||||||||||||||||||||||||||||||||||||
| (2) | Check the appropriate box if a member of a group (see instructions) (a) ☐ (b) ☐ | |||||||||||||||||||||||||||||||||||||
| (3) | SEC use only | |||||||||||||||||||||||||||||||||||||
| (4) | Citizenship or place of organization USA | |||||||||||||||||||||||||||||||||||||
Number of shares beneficially owned by each reporting person with: | (5) | Sole voting power 0 | ||||||||||||||||||||||||||||||||||||
| (6) | Shared voting power 1,478,286 | |||||||||||||||||||||||||||||||||||||
| (7) | Sole dispositive power 0 | |||||||||||||||||||||||||||||||||||||
| (8) | Shared dispositive power 1,478,286 | |||||||||||||||||||||||||||||||||||||
| (9) | Aggregate amount beneficially owned by each reporting person 1,478,286 | |||||||||||||||||||||||||||||||||||||
| (10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐ | |||||||||||||||||||||||||||||||||||||
| (11) | Percent of class represented by amount in Row (9) 4.96% (1) | |||||||||||||||||||||||||||||||||||||
| (12) | Type of reporting person (see instructions) CO | |||||||||||||||||||||||||||||||||||||
(1) Based on 29,780,409 shares of Common Stock issued and outstanding as of May 5, 2022, as reported in the Form 10-Q.
Page 3 of 7 pages
Explanatory Note:
This Amendment No. 2 (this “Amendment”) amends, in its entirety, the statement on Schedule 13G originally filed on November 6, 2019 by the Reporting Persons. This Amendment is being filed to disclose that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock of the Issuer, based upon 29,780,409 shares of Common Stock issued and outstanding as of May 5, 2022, as reported in the Issuer’s Form 10-Q, for the period ended March 31, 2022, filed with the Securities and Exchange Commission on May 11, 2022. This Amendment is the final amendment to the Schedule 13G and constitutes an exit filing for each Reporting Person.
Item 1(a) Name of issuer:
BiomX Inc. (the “Issuer”)
Item 1(b) Address of issuer’s principal executive offices
22 Einstein St.
5th Floor
Ness Ziona, Israel 7414003
Item 2(a) Name of person filing:
Takeda Pharmaceutical Company Limited
Takeda Ventures, Inc.
Item 2(b) Address of principal business office or, if none, residence:
Takeda Pharmaceutical Company Limited – 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan
Takeda Ventures, Inc. – 9625 Towne Centre Drive, San Diego, CA 92121, USA
Item 2(c) Citizenship:
Takeda Pharmaceutical Company Limited – Japan
Takeda Ventures, Inc. – USA
Item 2(d) Title of class of securities:
Common Stock
Item 2(e) CUSIP No.:
09090D103
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item 4. Ownership<
/div>
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: See the responses in Row 9 on the attached cover pages.
(b) Percent of class: See the responses in Row 11 on the attached cover pages.
(c) Number of shares as to which the person has:
Page 4 of 7 pages
(i) Sole power to vote or to direct the vote: See the responses in Row 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote: See the responses in Row 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of: See the responses in Row 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of: See the responses in Row 8 on the attached cover pages.
The percentages used herein and in this Item 4 are calculated based on 29,780,409 shares of Common Stock issued and outstanding as of May 5, 2022.
Item 5. Ownership of 5 Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
See Exhibit 99.1.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Page 5 of 7 pages
Signatures
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: August 4, 2022
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||||
| By | /s/ Yoshihiro Nakagawa | |||||||
| Name: | Yoshihiro Nakagawa | |||||||
| Title: | Corporate Officer, Global General Counsel | |||||||
| TAKEDA VENTURES, INC. | ||||||||
| By | /s/ Michael Martin | |||||||
| Name: | Michael Martin | |||||||
| Title: | President | |||||||
Page 6 of 7 pages
INDEX TO EXHIBITS
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company
Exhibit 99.2 Joint Filing Agreement (incorporated herein by reference to Exhibit 99.2 to the Schedule 13G filed on November 6, 2019, by the reporting persons with the Securities and Exchange Commission)